QAX576 ( DrugBank: - )

4 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
85	Idiopathic interstitial pneumonia	3
96	Crohn disease	3
98	Eosinophilic gastrointestinal disease	1

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00581997 (ClinicalTrials.gov)	December 2007	21/12/2007	QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis	A Randomized, Double-blinded, Placebo Controlled, Multiple-dose, Multi-center Pilot Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients With Pulmonary Fibrosis Secondary to System Sclerosis	Pulmonary Fibrosis Secondary to Systemic Sclerosis	Drug: QAX576;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	65 Years	Both	8	Phase 2	United States

85. Idiopathic interstitial pneumonia

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020688-18-GB (EUCTR)	29/06/2011	28/01/2011	Safety and Efficacy of QAX576 in Patients With Progressive Idiopathic Pulmonary Fibrosis (IPF)	A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics andpharmacokinetics of QAX576 in patients with rapidly progressive idiopathic pulmonary fibrosis	Patients with rapidly progressive idiopathic pulmonary fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders	Product Code: QAX576	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	40		United Kingdom
2	NCT01266135 (ClinicalTrials.gov)	December 2010	17/12/2010	Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF	Idiopathic Pulmonary Fibrosis	Drug: QAX576;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	18 Years	80 Years	All	40	Phase 2	United States;United Kingdom
3	NCT00532233 (ClinicalTrials.gov)	September 2007	19/9/2007	SD, IL-13 Production Rate in IPF	A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Drug: QAX576	Novartis Pharmaceuticals	NULL	Completed	40 Years	80 Years	All	52	Phase 2	United States

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01355614 (ClinicalTrials.gov)	June 2011	16/5/2011	A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients	A Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tolerability of the Anti-IL13 Monoclonal Antibody QAX576 in the Treatment of Perianal Fistulas in Patients Suffering From Crohn's Disease	Crohn's Disease	Drug: QAX576;Drug: Infliximab	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	10	Phase 2	Germany;Switzerland
2	EUCTR2010-019973-13-DE (EUCTR)	14/01/2011	30/09/2010	A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients	A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patients suffering from Crohn’s disease	Treatment of perianal fistulas in patients suffering from Crohn's Disease. MedDRA version: 14.0;Level: PT;Classification code 10016717;Term: Fistula;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.0;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders	Product Code: QAX576 Trade Name: Remicade INN or Proposed INN: INFLIXIMAB	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	23	Phase 2	Germany;Switzerland
3	NCT01316601 (ClinicalTrials.gov)	January 2011	14/3/2011	A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease		Crohn's Disease	Drug: QAX567	Gerhard Rogler	Novartis Pharmaceuticals	Completed	18 Years	N/A	Both	3	Phase 2	Switzerland

98. Eosinophilic gastrointestinal disease

Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01022970 (ClinicalTrials.gov)	November 2009	25/11/2009	Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis	A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)	Eosinophilic Esophagitis	Drug: QAX576 placebo;Drug: QAX576	Novartis Pharmaceuticals	NULL	Completed	18 Years	50 Years	All	25	Phase 2	United States